SAN DIEGO, Nov. 4 /PRNewswire-FirstCall/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced unaudited financial results for the three months ended September 30, 2009.
Three Months Ended September 30, 2009
As of September 30, 2009, Orexigen held $56.9 million in cash and cash equivalents and an additional $50.9 million in investment securities, available-for-sale. Together, these amounts total $107.8 million.
For the three months ended September 30, 2009, Orexigen reported a net loss of $14.4 million, or $0.33 per share attributable to common stockholders, compared to a net loss of $24.8 million, or $0.72 per share attributable to common stockholders, for the comparable period in 2008.
Total operating expenses for the three months ended September 30, 2009, were $14.2 million compared to $25.1 million for the comparable period in 2008. The decreased operating expenses were due primarily to a decrease in research and development expenses in connection with the completion of the Company's Contrave® Phase 3 clinical trials, related proprietary product formulation work and consulting activities totaling approximately $12.9 million. The decrease was partly offset by an increase in costs incurred in connection with the preparation of the Contrave NDA and an increase in salaries and personnel related costs. In addition, general and administrative expenses increased approximately $1.0 million due primarily to an increase in salaries and personnel related costs, legal and accounting fees, recruiting expense and facilities costs.
"The recent completion of the COR Phase 3 program and the Phase 2b trial of Empatic(TM) were major milestones for Orexigen," said Mike Narachi, President and CEO of Orexigen. "The results demonstrate the potential of these two product candidates to help fill the current gap in obesity treatment by providing physicians with useful pharmacologic options to address the varying needs of this diverse patient population. We believe that Contrave, if approved, has the potential to serve as the first-line treatment of obesity for the majority of patients, while Empatic can be developed and positioned in a highly complementary way."
Orexigen announced new data from the COR-I, COR-II and COR-Diabetes trials at Annual Scientific Meeting of The Obesity Society in late October. These new data show that after completing 56 weeks of therapy with Contrave32 (bupropion SR 360 mg/naltrexone SR 32 mg):
The most frequently observed treatment-emergent adverse events were nausea, constipation and headache. Nausea was the leading adverse event resulting in discontinuation; however, for the majority of patients experiencing nausea, it was mild to moderate, transient and manageable.
The results from the successfully completed COR program of more than 4,500 patients exceed the FDA categorical efficacy benchmark for clinically significant weight loss, supporting the Company's plan to file a New Drug Application with the FDA in the first half of 2010.
Orexigen recently announced the data from the Phase 2b clinical trial of Empatic. The results of this trial demonstrated that patients completing 24 weeks of Empatic360 (bupropion SR 360mg/zonisamide SR 360 mg) therapy lost 9.9% of their baseline body weight, or 22 pounds, compared to 1.7% for placebo patients (p<0.001). Importantly, Empatic patients continued to lose weight through the end of the trial, with no evidence of a weight loss plateau. Improvements were observed in key markers of cardiometabolic risk such as waist circumference, triglycerides, fasting insulin and blood pressure. The most commonly reported adverse events for all Empatic patients were headache, insomnia and nausea, and the most common adverse events leading to discontinuation were insomnia, headache and urticaria (hives). Adverse events and laboratory findings appeared to be consistent with the individual components of Empatic. There were no serious adverse events attributed by investigators to study drug. There were no statistically or clinically meaningful differences between Empatic and placebo on measures of cognitive function, depression, suicidality or anxiety.
Conference Call Today at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time)
The Orexigen management team will host a teleconference and webcast to discuss the third quarter 2009 financial results and recent business highlights. The live call may be accessed by phone by calling (866) 783-2138 (domestic) or (857) 350-1597 (international), participant code 88599521. The webcast can be accessed live on the investor relations section of the Orexigen web site at http://www.orexigen.com, and will be archived for 14 days following the call. The archive may be accessed by calling (888) 286-8010 (domestic) or (617) 801-6888 (international), participant code 25068077.
About Orexigen Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies that offer multiple approaches to treating obesity. The Company's lead investigational product, Contrave®, has completed the COR Phase 3 clinical development program and is on track for a regulatory submission with the FDA in the first half of 2010. The Company's second obesity drug candidate, Empatic(TM), has completed Phase 2 trials. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss, through combination therapeutic approaches. Further information about the Company can be found at http://www.Orexigen.com.
Orexigen cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward-looking statements. These statements are based on the Company's current beliefs and expectations. These forward-looking statements include statements regarding the efficacy and safety of Empatic(TM) and Contrave®, the potential for, and timing of, proceeding to Phase 3 clinical trials for Empatic or filing an NDA for Contrave, the commercial and therapeutic potential of Empatic and Contrave, and the potential to obtain regulatory approval for, and effectively treat obesity with, either product candidate. The inclusion of forward-looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risk and uncertainties inherent in the Orexigen business, including, without limitation: additional analyses of data from the Empatic Phase 2b trial or Contrave Phase 3 trials and any other clinical trials of Empatic or Contrave may produce negative or inconclusive results, or may be inconsistent with previously announced results or previously conducted clinical trials; the FDA may not agree with the Company's interpretation of efficacy and safety results; earlier clinical trials may not be predictive of future results; Empatic or Contrave may not receive regulatory approval on a timely basis or at all, and the FDA may require Orexigen to complete additional clinical, non-clinical or other requirements prior to the submission or the approval of NDAs for either product candidate; the potential for adverse safety findings relating to Empatic or Contrave to delay or prevent regulatory approval or commercialization, or result in product liability claims, including serious adverse events that are not characterized by clinical investigators as possibly related to Empatic or Contrave and adverse events associated with the individual components of these product candidates; the third parties on whom Orexigen relies to assist with the development programs for Empatic or Contrave, including clinical investigators, contract laboratories, clinical research organizations and manufacturing organizations, may not successfully carry out their contractual duties or obligations or meet expected deadlines, and the quality or accuracy of the data or materials generated by such third parties may be of insufficient quality to include in the Company's regulatory submissions; the ability of Orexigen and its licensors to obtain, maintain and successfully enforce adequate patent and other intellectual property protection of its product candidates; and other risks described in the Company's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Orexigen undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995. Information included herein is based on the Company's review and evaluation of the clinical data. All conclusions and determinations contained herein are subject to the Company's further analysis of the clinical data. The ultimate determination of the safety and efficacy of Contrave and Empatic will be made by the FDA and other relevant regulatory authorities.
Orexigen Therapeutics, Inc. (a development stage company) Balance Sheets (In thousands, except share and par value amounts) September 30, December 31, 2009 2008 ---- ---- (Unaudited) Assets Current assets: Cash and cash equivalents $56,936 $45,451 Investment securities, available-for-sale 50,859 40,716 Prepaid expenses and other current assets 1,980 1,184 ----- ----- Total current assets 109,775 87,351 Property and equipment, net 1,441 2,059 Restricted cash 1,290 1,375 Other assets 689 1,123 --- ----- Total assets $113,195 $91,908 ======== ======= Liabilities and stockholders' equity Current liabilities: Accounts payable and accrued expenses $10,562 $18,810 Deferred revenue, current portion 88 88 Long-term debt, current portion 7,184 7,591 ----- ----- Total current liabilities 17,834 26,489 Deferred revenue, less current portion 993 1,058 Long-term debt, less current portion 3,741 8,800 Other long-term liabilities 1,775 1,767 Commitments and contingencies Stockholders' equity: Preferred stock, $.001 par value, 10,000,000 shares authorized at September 30, 2009 and December 31, 2008; no shares issued and outstanding at September 30, 2009 and December 31, 2008 - - Common stock, $.001 par value, 100,000,000 shares authorized at September 30, 2009 and December 31, 2008; 47,039,720 and 34,433,322 shares issued and outstanding at September 30, 2009 and December 31, 2008, respectively 47 34 Additional paid-in capital 340,495 253,782 Accumulated other comprehensive income 27 153 Deficit accumulated during the development stage (251,717) (200,175) -------- -------- Total stockholders' equity 88,852 53,794 ------ ------ Total liabilities and stockholders' equity $113,195 $91,908 ======== ======= Orexigen Therapeutics, Inc. (a development stage company) Statements of Operations (In thousands, except per share amounts) (Unaudited) Period from Three Nine September Months Months 12, Ended Ended 2002 September September (Inception) 30, 30, to --------- --------- September 30, 2009 2008 2009 2008 2009 ---- ---- ---- ---- ----- Revenues: Collaborative agreement $- $- $- $- 174 License revenue 22 22 66 66 419 -- -- -- -- --- Total revenues 22 22 66 66 593 Operating expenses: Research and development 9,592 21,463 38,579 61,735 207,697 General and administrative 4,592 3,638 12,254 11,049 50,076 ----- ----- ------ ------ ------ Total operating expenses 14,184 25,101 50,833 72,784 257,773 ------ ------ ------ ------ ------- Loss from operations (14,162) (25,079) (50,767) (72,718) (257,180) Other income (expense): Interest income 47 662 295 2,800 8,974 Interest expense (318) (370) (1,070) (1,196) (3,511) ---- ---- ------ ------ ------ Total other income (expense) (271) 292 (775) 1,604 5,463 ---- --- ---- ----- ----- Net loss (14,433) (24,787) (51,542) (71,114) (251,717) Accretion to redemption value of redeemable convertible preferred stock - - - - (78) Deemed dividend of beneficial conversion for Series C preferred stock - - - - (13,860) -- -- -- -- ------- Net loss attributable to common stockholders $(14,433) $(24,787) $(51,542) (71,114) $(265,655) ======== ======== ======== ======== ========= Net loss per share attributable to common stockholders - basic and diluted $(0.33) $(0.72) $(1.38) $(2.12) ====== ====== ====== ====== Shares used in computing net loss per share attributable to common stockholders - basic and diluted 43,087 34,355 37,484 33,539 ====== ====== ====== ======
SOURCE Orexigen Therapeutics, Inc.
|SOURCE Orexigen Therapeutics, Inc.|
Copyright©2009 PR Newswire.
All rights reserved